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Selective stenting in subintimal angioplasty:
Analysis of primary stent outcomes
Gregory C. Schmieder, MD, Albert I. Richardson, MD, Eric C. Scott, MD, Gordon K. Stokes, MD,
George H. Meier III, MD, and Jean M. Panneton, MD, Norfolk, Va
Objective: Subintimal angioplasty (SIA) is being increasingly utilized to treat chronic arterial occlusions. The role of stents
in SIA is currently unknown. We performed a retrospective review of selective stent use in SIA to assess outcomes and
factors affecting these results.
Methods: A retrospective review of patient information—including demographics, indications, procedures, noninvasive
studies, and post-procedural events—was performed on our database for patients undergoing SIA in the superficial
femoral and popliteal arteries. Outcomes were calculated only on technically successful SIAs using Kaplan-Meier survival
analysis. Continuous and non-continuous data were compared using the Student t test and the z test, respectively.
Survival curves were compared using log-rank testing for univariate analysis and Cox hazard-regression analysis for
multivariate analysis.
Results: Three-hundred-sixty-eight patients (382 limbs) underwent femoral and/or popliteal SIA for critical limb
ischemia or disabling claudication from December 1, 2002 through July 31, 2006. Eighty-four limbs (22%) had a stent
placed, while 298 (78%) did not receive a stent. Mean follow-up was 11.7 months (range, 0-45 months). One-year
primary and secondary patency for stent vs no-stent group was 50% vs 45% (P  .73) and 70% vs 78% (P  .47),
respectively. One-year limb salvage rate for the stent vs no-stent group was 85% vs 90% (P  .61). At 2 years, patients
receiving a stent are more likely to undergo open bypass than those without a stent (P  .06). Eighty-three patients
underwent 84 SIA with stent placement. The mean number of stents for each case was 1.4  0.7. Univariate analysis
revealed that previous ipsilateral bypass surgery significantly decreased 1-year patency: 35% vs 56% (P  .05). SIA
performed for disabling claudication had a trend toward improved 1-year patency 58% vs 39% for critical limb ischemia
(P  .09). A stent diameter >7 mm displayed a trend toward better patency 53% vs 37% for diameter <6 mm (P  .08).
None of these factors proved significant with multivariate analysis.
Conclusion: Selective stents placed for suboptimal results after subintimal angioplasty produce similar patency rates to
primary SIA without stents. Patients receiving stents with prior lower extremity bypass surgery will have worse outcomes
than those without. Use of a stent diameter <6 mm and indication of critical limb ischemia will likely produce worse
results. It appears that other stent variables (location, number, length, and overlap) do not alter patency. Finally, selective
stent use after SIA provides excellent limb salvage. (J Vasc Surg 2008;48:1175-81.)Endovascular treatment for infrainguinal arterial occlu-
sive disease has been rapidly expanding over the last decade.
One technique, subintimal angioplasty (SIA), has been
increasingly utilized since its inception by Bolia in 1987.1
This technique creates a subintimal channel by dissection
and angioplasty. Over the last 20 years, stents have been
utilized for suboptimal results and, more recently, routinely
after SIA. Analysis of our first 105 SIAs with selective stent
use revealed a primary patency of 55% and 35% at 1-year
and 3-years, respectively.2 Limb salvage rate of 78% was
seen at 3 years.
Several studies have reported the use of stents both
selectively and routinely to supplement intraluminal bal-
loon angioplasty (IBA). Recent reports have supported
routine stenting after IBA.3-5 Other studies of IBA have
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Whether this intraluminal data can be extrapolated to SIA
and the factors that may impact the patency of stents in SIA
are still unknown. We performed a retrospective review of
our selective stent use in SIAs to assess outcomes and the
factors which may affect these results.
MATERIALS AND METHODS
A retrospective review was performed on patients with
critical limb ischemia or disabling claudication who under-
went a primary SIA from December 1, 2002 through July
31, 2006. Patient demographics, clinic notes, noninvasive
vascular studies, angiographic findings, and operative re-
ports were reviewed after approval by the Institutional
Review Board.
During this period, 639 consecutive SIAs were per-
formed on 591 patients with chronic arterial occlusive
disease. The occluded segments ranged from the common
iliac artery to the tibial arteries. This study focuses only on
those limbs in which a successful SIA was performed in the
superficial femoral and popliteal segments; hence, evaluat-
ing results of 382 limbs in 368 patients. In our practice,
patients with disabling claudication or critical limb ischemia
are routinely offered endovascular therapy as a first-line
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ably choose this option after discussion of surgical alterna-
tives.
All procedures were performed by vascular surgeons.
Most procedures were performed in an angiographic suite
and the remaining in an operating room with non-fixed
fluoroscopy if deep sedation or general anesthesia was
required or if a concomitant open operation was required.
There was no established protocol for the SIA technique or
use of stents. The general principles of creating a SIA
channel and use of a stent for a suboptimal result were
practiced by all physicians. The common femoral artery
contralateral to the treated limb was the preferred means of
angiographic access. After angiography and identification
of an arterial occlusion, patients were systemically heparin-
ized. The occluded segments were typically approached by
placement of a longer sheath over the aortic bifurcation and
in proximity to the occlusion. A soft, hydrophilic 0.035-
inch guidewire in combination with a 4F or 5F angled
hydrophilic catheter (Glidecath, Terumo Medical Corpo-
ration, Somerset, NJ) were the most commonly used to
perform the subintimal dissection. Other common cathe-
ters utilized during SIA include the Bernstein catheter
(Cook Medical; Bloomington, Ind) and the Quick-Cross
catheter (Spectranetics Corporation, Colorado Springs,
Colo). Passage of the guidewire along the medial, lateral,
anterior, or posterior border of the arterial wall, guidewire
advancement in a helical course across the lesion, and
injection of contrast demonstrating a dissection plane were
all indications of subintimal guidewire location. After con-
firmation of catheter re-entry into the true lumen just distal
to the arterial occlusion, balloon angioplasty was used to
dilate the subintimal channel. After SIA was completed, an
angiogram was performed to assess the results. Stents were
selectively deployed within segments of the channel for: (1)
suboptimal angioplasty, defined as residual stenosis greater
than 30%; (2) dissection flaps; and (3) calcification. Calci-
fication was used to denote lesions which were very difficult
to traverse in a subintimal channel and could visualize
severe calcified plaque on angiogram. Also, stents were
deployed only in suboptimal segments. When two or more
stents were used, they could be placed in a contiguous and
non-contiguous position depending upon focality and lo-
cation of the suboptimal segment. Self-expanding nitinol
stents were utilized for the majority of cases (n  111;
92%); the remaining cases used balloon-expandable stents
(n  4; 3%) or stent type could not be identified (5%).
Balloon expandable stents were utilized when accurate
deployment was necessary, such as at the bifurcation of the
common femoral artery into the superficial femoral artery
(SFA) and profunda femoral artery.
Adjunctive procedures utilized during the procedure
for the “stent” group included mechanical atherectomy
(2), mechanical thrombectomy (2), thrombolytic infusion
(3), cryoplasty (2), and laser atherectomy (2). Adjunctive
procedures were utilized to address a suboptimal result
determined by angiography. Approximately 3% of the no-
stent group required an adjunctive procedure; whereas, 8%in the stent group (excluding tissue plasminogen activator
[tPA]). Technical success was defined as the creation of a
subintimal channel bypassing the occlusion, with successful
re-entry into the true lumen and subsequent angioplasty.
Our immediate technical success has been previously pub-
lished at 87%.2 For this study, only patients with a techni-
cally successful SIA were evaluated. After the procedure,
patients received clopidogrel for at least 1 month and
aspirin indefinitely. Patients were allowed to resume ambu-
lation 6 to 8 hours after the procedure and were typically
discharged home within 24 hours.
Clinical follow-up at 1 month, 3 months, and 6 to 12
months after the procedure was routine and included phys-
ical examination andmeasurement of ankle-brachial indices
(ABI). Duplex scan examination of the subintimal channel
and further follow-up were obtained at the discretion of the
treating surgeon. The majority of surveillance for patency
was obtained through duplex scan examination and ABIs;
the rest was obtained via physical exam. “Non-operative”
candidates were defined as either prohibitive surgical risk
secondary to medical condition or were without surgical
bypass options. Any additional endovascular procedures to
maintain or restore patency of the subintimal channel were
recorded, as were all open surgical revisions, bypasses, and
major amputations performed through July 31, 2007.
Patency of the SIA was defined by at least one of the
following criteria: flow through the vessel demonstrated by
angiography or duplex ultrasonography scan, maintenance
of an ABI greater than 0.10 above the pre-procedural value,
or maintenance of a palpable pedal pulse that was absent
before the procedure in an asymptomatic patient. Resolu-
tion of symptoms was not considered an indication of
patency. Any follow-up intervention necessitating open
surgical revision or bypass was reported as such and was not
included in primary assisted or secondary patency. Symp-
tomatic improvement in patients with critical limb ischemia
was defined as the resolution of rest pain or healing of ulcers
and gangrenous wounds after debridement or minor am-
putation. Symptomatic improvement in patients with clau-
dication was defined as improvement in walking distance, as
determined through follow-up visits. Loss of symptomatic
improvement was used to calculate the maintenance of
claudication relief.
Continuous data are expressed as mean standard devi-
ation (SD) and were compared by using the Student t test.
Non-continuous data are expressed as percentages and
were compared by using the z test comparison for propor-
tions. A P  .05 was considered statistically significant.
Patency, limb salvage, symptomatic improvement, and free-
dom from surgical bypass were determined with Kaplan-
Meier survival analysis and compared by log-rank testing.
Multivariate analysis was performed by Cox proportional-
hazards regression. Patency is presented by efficacy analysis
and not intention to treat.
RESULTS
Analysis of no-stent vs stent. Three hundred sixty-
eight patients (382 limbs) underwent femoral and/or pop-
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from December 1, 2002 through July 31, 2006. Eighty-
four limbs (22%) had a stent placed, while 298 (78%) did
not receive a stent. Mean follow-up was 11.7 months
(range, 0-45 months). Patient demographics are presented
in Table I. Patients who received a stent had a mean age of
67.6  13.2, while those who did not receive a stent had a
mean age of 69.2  11.7 (P  NS). The stent group had
statistically significant more patients with hyperlipidemia
(48% vs 35% [P  .05]) and a history of smoking than the
non-stent group (58% vs 46% [P  .05]). There was also a
trend for more patients in the stent group who had under-
gone a prior lower extremity bypass than the non-stent
group (27% vs 18% [P  .07]).
One-year primary patency for the stent vs the no-stent
group was 50% vs 45%, respectively (P  .73) (Fig 1). The
1-year secondary patency for the stent vs the no-stent group
was 70% vs 78% (P  .47), respectively (Fig 2). Twenty-
eight percent (n  79) of patients in the no-stent group
underwent a re-intervention, while 25% (n  21) in the
stent group required a re-intervention (PNS). There was
no statistically significant difference in technical success
rates between the two groups. In patients with critical limb
ischemia, the 1-year limb salvage rate for the stent vs the
no-stent group was 85% vs 90% (P .61), respectively (Fig
3). Only 1 patient treated for claudication required an
Table I. Patient demographics and risk factors for
peripheral arterial disease
Variable
No-stent
(limbs-298;
285 pts)
†
Stent
(limbs-84;
83 pts)
P-
value
Age (years)
Mean  SD 69.2  11.7 67.6  13.2 .27
Range 38.4-98.9 40.6-98.4 —
Male gender 52% (155) 61% (51) .16
Indication
Critical limb ischemia 58% (172) 49% (41) .15
Rest pain 24% (70) 20% (17) .53
Ulceration 25% (75) 17% (14) .10
Gangrene 9% (27) 12% (10) .44
Claudication 42% (125) 50% (42) .19
Risk factors
Hypertension 68% (194) 71% (58) .76
Diabetes mellitus 50% (142) 43% (36) .32
Coronary artery disease 53% (152) 48% (40) .35
History of smoking 46% (132) 59% (49) .05
End-stage renal disease 11% (32) 12% (10) .67
Hyperlipidemia 35% (99) 47% (39) .04
Previous LE bypass 18% (52) 27% (22) .07
Nonoperative candidate 14% (41) 10% (8) .27
Location of SIA
SFA only 50% (148) 57% (48) .23
SFA-popliteal 47% (139) 39% (33) .23
Popliteal only 3% (11) 4% (3) .96
LE, Lower extremity; SC, standard deviation; SIA, subintimal angioplasty;
SFA, superficial femoral artery.
†Patient demographics calculated by number of patients; procedural char-
acteristics calculated by number of limbs.amputation 35 months after the procedure. Maintenanceof claudication relief for the stent vs the no-stent group was
83% vs 89% (P  .54). At 2 years, there was a trend for
better freedom from bypass surgery in the no-stent group vs
the stent group (83% vs 65%, respectively; P .06) (Fig 4).
Two patients (2.3%) in the stent group encountered
procedural complications which both required endovascu-
lar therapy; a distal embolus treated with thrombolysis and
a fractured glidewire retrieved with a snare wire. Eleven
patients (3.7%) in the no-stent group had procedural com-
plications: hematoma (3), pseudoaneurysm (2), arterial
perforation (2), distal embolus (1), arteriovenous fistula
(1), wound infection (1), and a contralateral iliac artery
dissection (1). Two complications required surgical inter-
vention; evacuation of a retroperitoneal hematoma and
repair of an iliac artery dissection. Periprocedural mortality
was similar between the two groups (1.2% stent and 0.7%
no-stent; PNS). During the study, there were 50 deaths;
6 in the stent group and 44 in the no-stent group. The
majority of deaths occurred in patients treated for critical
Fig 1. Primary patency of stent vs no-stent group. One-year
patency stent 50% vs no-stent 45% (P  .73).
Fig 2. Secondary patency of stent vs no-stent group. One-year
patency stent 70% vs 77% (P  .47).limb ischemia (44), whereas only six deaths occurred in
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10.7  9.7 months (range, 0.2-35.2).
Analysis of stent group. Eighty-three patients under-
went 84 SIA with primary stent placement. Stent charac-
teristics are presented in Table II. The mean number of
stents used for each case was 1.4  0.7 (range, 1-5). The
mean stent diameter utilized during the study was 7 mm
(range, 5 mm-8 mm). The total length of the stent used in
each case averaged 89 mm 62 (range, 15 mm-300 mm).
In those patients who had multiple stents deployed, 73%
required overlap. The other 27% with multiple stents
did not overlap secondary to stent placement in non-
contiguous, treated segments. For example, two stents
placed separately in the proximal and distal segment of the
SFA would not overlap.
The locations of stent deployment were the superficial
femoral artery only 79% (67), the SFA-popliteal segments
10% (8), and the popliteal artery only 11% (9). For purposes
of patency analysis, the femoro-popliteal segments were
Fig 3. Limb salvage for CLI patients of stent vs no-stent group.
One-year stent 85% vs no-stent 90% (P  .61).
Fig 4. Freedom from bypass surgery. Two-year rate stent (65%)
vs no-stent (83%) (Log rank P  .06).divided into: (1) proximal (SFA-proximal and middle seg-ments; n 34) and (2) distal (SFA-distal and popliteal; n
39). Eleven patients were not included in this data; 7 had
stents placed throughout the channel, while the other 4
patients had stents placed at the proximal and distal aspects
of the SIA channel. The indications for stent use were
suboptimal angioplasty (60%), dissection flap (38%), and
severe calcification (8%). In some cases, multiple indica-
tions were given for the same segment or for two separate
lesions. The amount of calcium in the occluded arterial
segment was not quantified. Also, calcification was always
used in conjunction with a suboptimal angioplasty as an
indication for stent use. Univariate analysis revealed that a
patient who had a previous, ipsilateral, lower extremity
bypass surgery had significantly decreased 1-year patency
(35%) vs those without a previous bypass (56%) [P  .05].
Also, patients who had a SIA performed for disabling
claudication had a trend toward improved 1-year patency
(58%) vs critical limb ischemia (39%) (P  .09). In addi-
tion, a stent diameter 7 mm displayed a trend toward
better patency 53% vs 37% for a stent diameter6mm (P
.08). Univariate analysis did not reveal any other procedural
or demographic factors which affected patency rates in SIA
with stents (Table III). Multivariate analysis did not reveal
any significant factors affecting patency.
DISCUSSION
Endovascular therapy of peripheral arterial disease con-
tinues to expand into more complex lesions. One tech-
nique, SIA, is increasingly being used for such therapy.
Previously published series have shown 1-year primary pa-
tency and limb salvage rates of 51-80% and 85-94%, respec-
tively.1-2,7-9 Our results in this study affirm these outcomes
Table II. Characteristics of stent group
Variable Data
Number of stents
Mean 1.4  0.7
Range 1-5
Stent diameter
Mean 7.0 mm  0.9
Range 5 mm-8 mm
Stent length
Mean 89 mm  62
Range 15 mm-300 mm
Stent location*
SFA 79% (67)
SFA-popliteal 10% (8)
Popliteal 11% (9)
Stent overlap
†
73% (22)
Indication for stent**
Suboptimal angioplasty 60% (50)
Dissection flap 38% (32)
Severe calcification 8% (7)
*SFA (superficial femoral artery) indicates stents place in the proximal, mid,
and distal segments of SFA.
†Stent overlap-calculated for patients with multiple stents (n  30).
**Some limbs had more than one indication for the stent, ex. Suboptimal
result and severe calcification in the same or separate segments.and show that there is no statistical significant difference
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stents placed selectively.
While the role of stent placement after SIA is unknown
and has not been widely studied, its role in intraluminal
therapy has been evaluated. Only two published studies on
SIA report use of stents and their impact. The largest
reported experience is from Treiman and all other studies
are hard to interpret their results. Physicians are currently
using intraluminal stent data to justify stent use in SIA.
Schillinger et al4 reported decreased rates of restenosis at 6
months (23% vs 43%) and 1 year (37% vs 63%) in patients
receiving stents vs those with just balloon angioplasty in the
superficial femoral artery; however, there were no differ-
ences between the groups for relief of claudication or limb
salvage. Lower rates of re-intervention and recurrent steno-
sis in the femoro-popliteal segments have been seen up to 2
years in primary stenting after angioplasty compared to
angioplasty alone.5 Ferreira et al3 have also reported 5-year
assisted patency rates of 90% after IBA with the stent in the
SFA. It appears that stents aid patency rates; however, other
studies have shown their limitations. Surowiec et al6 have
shown that patency rates in the SFA after IBA with stents
decrease as the Trans-Atlantic Inter-Society Classification
(TASC) grade increases. In addition, the femoral artery
stenting trial (FAST) trial has shown no benefit of stent
over IBA at 1 year for short SFA lesions.10 As we continue
to define the role of stents in IBA, the applicability of these
results to SIA remain questionable. First, the lesion mor-
phology after angioplasty is different. The atherosclerotic
plaque remains in the flow channel after intraluminal an-
gioplasty, whereas a subintimal flow channel is devoid of
exposed plaque except at entry and re-entry points. This
Table III. Univariate analysis of risk factors for loss of
primary patency with stent use
Risk factor HR 95% CI P-value
CAD 0.71 0.35-1.39 .31
Female 1.36 0.70-2.71 .35
African American 0.77 0.39-1.52 .46
HTN 1.25 0.58-2.70 .57
Age 80 0.76 0.62-2.74 .49
Smoking 1.14 0.58-2.22 .70
Hyperlipidemia 1.39 0.71-2.78 .33
End-stage renal disease 0.99 0.80-3.23 .99
Diabetes mellitus 1.12 0.44-1.76 .72
Prior bypass surgery 1.92 0.99-4.76 .05
Critical limb ischemia 1.75 0.91-3.56 .09
Non-operative candidate 1.88 0.68-7.90 .18
Stent length
60 0.81 0.40-1.62 .55
100 1.14 0.63-2.11 .93
150 1.32 0.61-3.11 .44
Stent number 2 1.43 0.73-2.94 .28
Stent location- distal 0.79 0.37-1.59 .48
Stent overlap 1.20 0.38-1.77 .61
Stent diameter 6 mm 1.82 0.93-4.06 .08
Stent indication - dissection 1.55 0.80-3.22 .18
CAD, Coronary artery disease; HTN, hypertension.could alter arterial wall remodeling after SIA from thoseobservedwith IBA.Hence, the role of neo-intimal hyperplasia
after stent placement in a subintimal channel is unknown.
Second, the types of lesions in each group are different.
Whereas IBA can be used for segments with stenosis or short
occlusions, SIA is used for segments with short or long occlu-
sions. Also, as suggested by the worsening stent results with
increasing TASC lesion, themajority of SIA are performed for
TASC C and D lesions. Hence, the results from IBA stents
can’t be readily extrapolated to SIA.
Our results have shown that prior bypass surgery can
adversely affect outcomes in patients with stent use. Walker et
al11 also discovered poor patencies in 12 patients undergoing
SIA without stents after occluded vascular grafts. Worse pa-
tency may be related to progression of atherosclerosis in that
arterial segment or to neo-intimal hyperplasia near the anas-
tomotic site. This study also showed a trend towardworsening
patency in patients with critical limb ischemia compared to
claudication. Other papers on SIA have also shown similar
trends.12-15 There also appears to be a trend forworse patency
with smaller stents. This finding, however, may be con-
founded by vessel lumen. Hence, smaller stents may just
reflect placement of stents in smaller or more distal vessels.
Treiman et al16 studied 29 patients who received routine
stents after SIA and found good short-term patency rates of
85% and 64% at 1- and 2-years, respectively. The long-term
patency rates, however, declined precipitously to 18% and 9%
at 3- and 4-years.16 No further subanalysis of factors affecting
outcomeswas performed secondary to small numbers. Several
important points need to be discussed. First, long-term out-
comes after SIA are unknown. We have shown a primary
patency of 55% and 35% at 1 year and 3 years, respectively,
using selective stenting.2While our early primary patency rates
are not equal to Treiman’s at 1 year, our primary patency rates
are superior at 3 years. Therefore, stents may improve short-
term patency due to prevention of recoil, but sacrifice long-
term patency by inducing neo-intimal hyperplasia.
Second, it has been our view that stents may hinder any
secondary interventions. Our study, however, shows that
re-interventions can be undertaken with similar success
rates as those limbs without stents. Third, one putative
benefit of SIA is the maintenance of and possible opening
up of collaterals.17 The fate of these collaterals could be
jeopardized by placing stents. In our study, there was a
trend for SIA patients receiving stents (35%) to require
more open bypass surgery than those without stents (17%)
at 2 years (P  .06). This trend could reflect our bias that
endovascular reinterventions may be more difficult after
stent failure. Hence, patients with failed stents may un-
dergo open bypass surgery without an endovascular salvage
attempt. Finally, Treiman’s study lined the whole subinti-
mal channel with stents, whereas we selectively placed
stents in segments as needed. Hence, comparisons of SIA
with stent cannot be made between the studies. The bene-
fits and drawbacks of either approach are uncertain and
remain an important question to address.
There are several limitations of our study. First, its retro-
spective design contributed to incomplete data collection for
some preprocedural and postprocedural variables. This could
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low-up. Second, our study is the largest series of SIA under-
going selective stenting, but some variables had small num-
bers after partitioning. Therefore, any subanalysis performed
could underestimate the effect a variable imparts on patency.
Third, the incomplete and short-term follow-up limits the
applicability to long-term outcomes. Fourth, this study was
not designed to compare routine placement of stents vs place-
ment of selective or no stents. Our practice utilizes selective
placement of stents for a suboptimal result after SIA. While
there are defined criteria for suboptimal results, completion
angiogram interpretation after SIA remains quite subjective;
hence, leading to variable stent use by different surgeons.
Fifth, a wide variety and lengths of stents were utilized during
the study. The variability of performance between the differ-
ent types and lengths of stents may have confounded the
outcomes in the stent group. In addition, the difference in
stent lengths reflects both differences in the patient’s disease
processes and our bias to stenting only suboptimal segments.
Finally, there is a possibility of a type 2 error, especially in
subgroup analysis. This study, however, presents the largest
reported series on selective stenting after SIA; hence, the
possibility of a type 2 error is small.
Our study shows that selective stent placement can
salvage poor outcomes after SIA. This study neither affirms
nor refutes routine use of stents after SIA. A randomized
study comparing routine vs selective stent placement is
required to answer this important question.
CONCLUSIONS
Selective stents placed for suboptimal results after subintimal
angioplasty produces similar patency rates to primary SIA with-
out stenting. Patients with prior lower extremity bypass who
receive a stent after SIA will have worse patency than those
without prior bypass. Use of a stent diameter 6 mm and
indication of critical limb ischemia will likely produce worse
patency. Also, it appears that other specific stent variables (loca-
tion, number, length, and overlap) do not alter patency. Finally,
selective stent use after SIA provides excellent limb salvage.
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Gregory J. Pearl (Dallas, Tex). Dr. Schmieder and colleagues
report a large series of 368patients undergoing subintimal angioplasty
in superficial femoral and popliteal arteries. The purpose of the study
was to retrospectively review the selective use of stents and assess thelimbs, 84 (22%) received a stent and298 (78%) did not require a stent.
Stents were selectively placed for suboptimal results defined as greater
than 30% residual stenosis, dissection flaps or calcification.
One-year primary and secondary patency for the stent vs. no
stent groups was 50% vs. 45% and 70% vs. 78% respectively, the
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 5 Schmieder et al 1181differences of which were not statistically significant. One-year
limb salvage rates between the stent and no stent group were also
comparable at 85% and 90% respectively, again with no statistical
difference. Maintenance of claudication relief and freedom from
bypass at one year were also comparable between the two groups.
Analysis of various factors revealed that the patency rates in
claudicants trended higher than for patients with limb threatening
ischemia at one year; that patients who had a previous ipsilateral
lower extremity bypass exhibited decreased one year patency com-
pared to those without a prior bypass; and that a stent diameter of
at least 7 mm displayed a trend toward better patency. Stent
length, overlap vs. non-overlap, and stent location did not appear
to be significant factors in the outcome.
I have two questions for the authors:
1) During the 3½ years time frame of the study, 639 limbs were
treated at your institution with subintimal angioplasty, a huge
number by anyone’s estimate. The mean follow-up time of the
patients in this study was just 10.9 months. The one-year
patency rates for this procedure is significantly inferior to
commonly accepted one-year patency rates for fem-pop bypass,
so my first question relates to the number of fem-pop bypasses
performed during this same time frame at your institution to
help us decipher your approach to the symptomatic patient
with long segment SFA occlusive disease. That is, what patients
in your practice will go to the endo suite and which will be
taken to the OR? For example, do you pursue an endovascular
approach first and reserve open bypass only for technical failures
or do you follow an algorithm based on patient comorbidities,
presence of suitable autogenous bypass conduit, runoff scores,
etc that you could share with us?
2) Second, I believe your study shows that stens may be used
successfully to salvage unacceptable angiographic results of SIA
to achieve comparable outcomes to SIA and PTA alone. You
acknowledge in the manuscript that this neither affirms nor
refutes the use of stents after SIA and that a prospective
randomized trial may be required. But based on inferior pa-
tency rates of SIA compared to known patency of fem-pop
bypass, especially over longer follow-up periods, don’t you
think prospective randomized trial comparing SIA and fem-
pop bypass might be more meaningful?I want to thank the authors for sending the manuscript for my
review in advance and congratulate them on a fine study.Gregory C. Schmieder. First, regarding the number of open
bypasses performed. We perform approximately 100-125 femoro-
popliteal and femorotibial bypasses per year.
Second, our approach to infrainguinal occlusive disease is to
be very aggressive with endovascular therapies. An endovascular
approach is pursued in selected patients who do not have a good
autogenous conduit, ie, previous CABG or bypass procedure,
and/or who are not good operative candidates. Patients with
critical ischemia have a high mortality at 3 years, approximately
40%. In addition, perioperative mortality and woundmorbidity for
open bypass has been cited as 2-5% and 10-15%, respectively. The
goal of therapy in this patient group is to preserve the limb. We feel
that we can provide excellent limb salvage for these patients at
lower morbidity and mortality. We have expanded this bias of
decreased morbidity and mortality out to patients with claudica-
tion. In addition, we are still preserving a vein for a bypass graft
down the road.
Third, as for looking at parameters on the angiogram to
pursue or not to pursue SIA, we are looking for distal targets. If
there is any distal target that we can re-enter into, we have an 88%
success rate with this intervention; so there is a subset of patients in
whom we cannot successfully perform a SIA. We are currently
trying to define angiographic parameters which can help us identify
patients with poor outcomes.
Fourth, our patency rates for SIA are inferior to standard open
autogenous bypass surgery. Should we not focus more on patient’s
clinical outcomes instead of patency rates? Is the patient’s relief of
claudication or limb salvagemore important to the patient than the
patency rate? Also, it takes longer for patients to recover from an
open bypass surgery than an endovascular procedure. SIA is a same
day procedure after which patients go home and resume activities
sooner than open bypass. When patients are seen in the office, both
endovascular and open options are discussed. We stress the advan-
tages and disadvantages of each approach; endovascular with less
morbidity, shorter hospital stay, quicker return to activity, but less
durability versus open surgery with more morbidity, longer hospi-
tal stay, slower return to activity, but longer durability. Another
putative advantage of endovascular therapy is the ability to re-
intervene and still keep an open surgical option available. The
overwhelming majority of patients chose the endovascular option.
Hence, a randomized, prospective study between open bypass and
SIA would be difficult to perform because most patients would not
consent to be randomized to a possible open intervention.
